Allergy Therapeutics has announced a trading update for the year ended 30 June 2016. Reported revenues are expected to be slightly ahead of consensus expectations at £48.5m (PGe £48.1m, FY15: £43.2m), reaffirming the strength of sales commentary made most recently within the company’s 27 June 2016 release. This represents a reported YOY growth rate of +12% despite the negative impact of the weakening Euro throughout most of FY16, and a constant currency growth rate of
